Dyadic International (DYAI) Competitors $1.10 -0.02 (-1.79%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$1.08 -0.02 (-1.82%) As of 07/25/2025 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DYAI vs. HURA, BHST, ACTU, CTNM, ANIX, CTOR, ATOS, SAVA, CRBP, and HLVXShould you be buying Dyadic International stock or one of its competitors? The main competitors of Dyadic International include TuHURA Biosciences (HURA), BioHarvest Sciences (BHST), Actuate Therapeutics (ACTU), Contineum Therapeutics (CTNM), ANIXA BIOSCIENCES (ANIX), Citius Oncology (CTOR), Atossa Genetics (ATOS), Cassava Sciences (SAVA), Corbus Pharmaceuticals (CRBP), and HilleVax (HLVX). These companies are all part of the "pharmaceutical products" industry. Dyadic International vs. Its Competitors TuHURA Biosciences BioHarvest Sciences Actuate Therapeutics Contineum Therapeutics ANIXA BIOSCIENCES Citius Oncology Atossa Genetics Cassava Sciences Corbus Pharmaceuticals HilleVax TuHURA Biosciences (NASDAQ:HURA) and Dyadic International (NASDAQ:DYAI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk. Do institutionals & insiders hold more shares of HURA or DYAI? 0.6% of TuHURA Biosciences shares are owned by institutional investors. Comparatively, 28.0% of Dyadic International shares are owned by institutional investors. 0.2% of TuHURA Biosciences shares are owned by insiders. Comparatively, 29.5% of Dyadic International shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts prefer HURA or DYAI? TuHURA Biosciences currently has a consensus target price of $12.67, suggesting a potential upside of 344.44%. Dyadic International has a consensus target price of $6.00, suggesting a potential upside of 445.45%. Given Dyadic International's higher possible upside, analysts clearly believe Dyadic International is more favorable than TuHURA Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TuHURA Biosciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.40Dyadic International 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is HURA or DYAI more profitable? TuHURA Biosciences has a net margin of 0.00% compared to Dyadic International's net margin of -163.94%. TuHURA Biosciences' return on equity of 291.69% beat Dyadic International's return on equity.Company Net Margins Return on Equity Return on Assets TuHURA BiosciencesN/A 291.69% 122.09% Dyadic International -163.94%-233.69%-59.37% Which has stronger earnings & valuation, HURA or DYAI? Dyadic International has higher revenue and earnings than TuHURA Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTuHURA BiosciencesN/AN/A-$21.68MN/AN/ADyadic International$3.49M9.48-$5.81M-$0.20-5.50 Does the media refer more to HURA or DYAI? In the previous week, TuHURA Biosciences had 4 more articles in the media than Dyadic International. MarketBeat recorded 5 mentions for TuHURA Biosciences and 1 mentions for Dyadic International. Dyadic International's average media sentiment score of 1.89 beat TuHURA Biosciences' score of 0.68 indicating that Dyadic International is being referred to more favorably in the news media. Company Overall Sentiment TuHURA Biosciences Positive Dyadic International Very Positive Which has more volatility and risk, HURA or DYAI? TuHURA Biosciences has a beta of 0.17, indicating that its stock price is 83% less volatile than the S&P 500. Comparatively, Dyadic International has a beta of 0.88, indicating that its stock price is 12% less volatile than the S&P 500. SummaryTuHURA Biosciences and Dyadic International tied by winning 7 of the 14 factors compared between the two stocks. Get Dyadic International News Delivered to You Automatically Sign up to receive the latest news and ratings for DYAI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DYAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DYAI vs. The Competition Export to ExcelMetricDyadic InternationalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$33.70M$3.07B$5.70B$9.50BDividend YieldN/A2.37%4.69%4.01%P/E Ratio-5.5021.1828.1020.06Price / Sales9.48283.55428.7189.10Price / CashN/A42.7636.2258.56Price / Book13.758.378.665.87Net Income-$5.81M-$55.19M$3.25B$258.55M7 Day Performance12.96%5.88%4.22%3.73%1 Month Performance10.55%17.33%10.51%11.75%1 Year Performance-29.03%4.42%34.40%18.02% Dyadic International Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DYAIDyadic International3.2916 of 5 stars$1.10-1.8%$6.00+445.5%-22.0%$33.70M$3.49M-5.507Positive NewsGap DownHURATuHURA Biosciences1.7792 of 5 stars$2.55-2.7%$12.67+396.7%N/A$114.44MN/A0.00N/ABHSTBioHarvest SciencesN/A$6.84-1.2%$13.67+99.8%N/A$113.66M$25.19M-13.68N/ANews CoverageACTUActuate Therapeutics2.3747 of 5 stars$5.66-1.7%$20.50+262.2%N/A$113.01MN/A0.0010News CoverageCTNMContineum Therapeutics3.3652 of 5 stars$5.65+29.9%$22.50+298.2%-72.6%$112.54MN/A-2.8731High Trading VolumeANIXANIXA BIOSCIENCES3.0898 of 5 stars$3.43-0.3%$9.00+162.4%+11.4%$110.81M$210K-9.035Positive NewsCTORCitius Oncology1.6958 of 5 stars$1.48-3.3%$3.00+102.7%N/A$109.47MN/A0.00N/APositive NewsGap UpATOSAtossa Genetics3.0234 of 5 stars$0.85+0.8%$6.17+626.6%-40.4%$108.75MN/A-4.048News CoveragePositive NewsSAVACassava Sciences4.1424 of 5 stars$2.30+4.1%$54.50+2,269.6%-81.6%$106.76MN/A-1.5330Positive NewsCRBPCorbus Pharmaceuticals4.792 of 5 stars$8.56+0.7%$50.88+494.3%-83.3%$104.02MN/A-2.0340HLVXHilleVax1.9781 of 5 stars$2.05-0.5%$2.00-2.4%+15.0%$103.29MN/A-0.9520 Related Companies and Tools Related Companies TuHURA Biosciences Alternatives BioHarvest Sciences Alternatives Actuate Therapeutics Alternatives Contineum Therapeutics Alternatives ANIXA BIOSCIENCES Alternatives Citius Oncology Alternatives Atossa Genetics Alternatives Cassava Sciences Alternatives Corbus Pharmaceuticals Alternatives HilleVax Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DYAI) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredStrait of Hormuz = $100 Oil?Dow Drops 540 Points, Oil Soars Middle East conflict sends markets plunging, oil jumping 8.5%. Investors fl...The Oxford Club | SponsoredThe AI Chip Trade is OUT. This is in…Investing Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredElon Musk: “This will transform civilization as we know it.”Robots are no longer science fiction — they’re the next trillion-dollar megatrend. According to Forbes, by ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyadic International Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dyadic International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.